NOVAVAX INC

Novavax Inc. specializes in the research, development, and manufacturing of advanced biological therapeutics and pharmaceutical vaccines, with deep expertise in recombinant protein platforms and adjuvant technologies. The company designs and produces next-generation vaccine candidates, including COVID-19 formulations for both adult and pediatric populations, leveraging scalable biomanufacturing processes for biological products exempt from diagnostic use. Their technical capabilities span end-to-end vaccine development—from antigen design and preclinical validation to GMP-compliant production and regulatory-ready formulation—positioning them as a specialized provider of immunobiological solutions for public health emergencies and chronic disease prevention. Novavax maintains a strong, sustained relationship with the Department of Health and Human Services, delivering critical vaccine manufacturing and biomedical development services, particularly in pandemic response and pediatric immunization programs. They also support the Department of Defense in vaccine innovation and the Department of Veterans Affairs through pharmaceutical supply contracts for hematologic and specialty drug products, demonstrating adaptability across federal health security and clinical care missions. The contractor’s primary industry focus lies in biological product manufacturing and pharmaceutical preparation, with a clear specialization in infectious disease vaccines and biologics production. Their work centers on non-diagnostic biologics, including protein-based immunogens and stabilized formulations, placing them at the intersection of biotechnology R&D and regulated manufacturing. This positions Novavax as a niche provider for government agencies requiring advanced vaccine platforms beyond traditional platforms. As a Maryland-based entity structured as a 2L corporation, Novavax operates with a focused, mission-driven profile in the federal biopharmaceutical market. While no government certifications are listed, their consistent performance on high-stakes, complex contracts underscores their compliance with FDA, CDC, and DOD regulatory frameworks for biological product development and supply chain integrity.